Abbott Challenges $1.67 Billion Patent Loss to J&J Over Humira

Abbott Laboratories urged a U.S. appeals court to throw out a $1.67 billion patent-infringement verdict, the largest in U.S. history, set after a jury found the company used Johnson & Johnson’s technology to develop the arthritis drug Humira.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.